Priliximab

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease [cite journal |author=Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S |title=CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study |journal=Gut |volume=40 |issue=3 |pages=320–7 |year=1997 |pmid=9135519] and multiple sclerosis [cite journal |author=Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M |title=Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412 |journal=Neurology |volume=48 |issue=4 |pages=810–6 |year=1997 |pmid=9109860] [cite journal |author=van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr H, Polman C |title=Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial |journal=Neurology |volume=49 |issue=2 |pages=351–7 |year=1997 |pmid=9270561] but has not yet received FDA licencing. The patent belongs to the biotechnology company Centocor.

References